Zentalis Pharmaceuticals shares are trading higher after Wedbush maintained a Neutral rating on the stock and raised its price target from $12 to $15.
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals' stock price increased following Wedbush's decision to maintain a Neutral rating but raise its price target from $12 to $15.
February 28, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zentalis Pharmaceuticals' stock price is likely to experience short-term positive momentum due to Wedbush's raised price target from $12 to $15, despite maintaining a Neutral rating.
The increase in Zentalis Pharmaceuticals' stock price can be attributed to Wedbush's raised price target, which signals a positive reassessment of the company's value. Despite the Neutral rating, the higher price target suggests that Wedbush sees more potential in the stock than previously, which can lead to increased investor confidence and buying activity in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90